$324 Million is the total value of Abingworth LLP's 19 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte | $93,629,000 | +14.0% | 4,168,718 | 0.0% | 28.94% | +2.0% | |
| PHAT | Phathom | $40,726,000 | -9.6% | 1,203,135 | 0.0% | 12.59% | -19.1% | |
| Spruce Bio | $20,076,000 | -32.5% | 1,792,518 | 0.0% | 6.21% | -39.6% | ||
| SIEN | Sientra | $19,031,000 | +9.6% | 2,390,843 | 0.0% | 5.88% | -1.9% | |
| SRRA | Sierra Oncology | $16,813,000 | +14.2% | 871,125 | 0.0% | 5.20% | +2.2% | |
| ACET | Adicet | $16,574,000 | -21.0% | 1,615,385 | 0.0% | 5.12% | -29.3% | |
| VRNA | Veronasponds adr | $15,998,000 | -21.1% | 2,457,499 | 0.0% | 4.94% | -29.4% | |
| SLNO | Soleno | $11,642,000 | -10.3% | 10,302,602 | 0.0% | 3.60% | -19.7% | |
| XCUR | Exicure | $10,396,000 | -31.3% | 6,977,000 | 0.0% | 3.21% | -38.5% | |
| NCNA | Nucanaadr | $9,200,000 | -44.5% | 3,333,333 | 0.0% | 2.84% | -50.3% | |
| PRTK | Paratek | $7,090,000 | -3.3% | 1,041,131 | 0.0% | 2.19% | -13.4% | |
| AGLE | Aeglea | $1,671,000 | -11.8% | 240,500 | 0.0% | 0.52% | -20.9% | |
| MTEM | Molecular Templates | $1,564,000 | -37.7% | 200,000 | 0.0% | 0.48% | -44.4% | |
| XFOR | X4 Pharma | $1,494,000 | -23.6% | 229,885 | 0.0% | 0.46% | -31.7% | |
| CBAY | Cymabay | $571,000 | -4.0% | 131,036 | 0.0% | 0.18% | -13.7% | |
| OBSV | Obseva | $266,000 | -7.0% | 87,999 | 0.0% | 0.08% | -17.2% | |
| HSGX | Ocugen | $57,000 | +18.8% | 7,111 | 0.0% | 0.02% | +5.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.